Clinical trial · Interventional
PCOS Immune Function Predicts Metformin Efficacy
Prediction of Immune Status on the Efficacy of Metformin in the Treatment of Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, the investigators will include PCOS patients who meet the trial criteria, introduce participants to the content of this study, and invite participants to participate. The immune function of peripheral blood samples of PCOS patients was detected by flow cytometry. Participants were further treated with metformin for 6 months and followed up after the intervention. The objective of this study was to investigate immune markers related to the efficacy of metformin in PCOS patients and to predict the efficacy of metformin in PCOS patients using immune function.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Immune Function | — | UNRESOLVED | — |
| Metformin | — | UNRESOLVED | — |
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Metformin therapy
- description
- Metformin intervention, 1000mg daily for the first week, 1500mg daily starting in the second week until six months of treatment.
- interventionNames
- Drug: Metformin
Primary outcomes (2)
- measure
- The number of cell groups expressing different markers were counted by the fluorescence detection system on flow cytometry.
- timeFrame
- Samples to be collected once per participant within 7 days of enrollment.
- description
- Flow cytometry was used to detect the antigenic antibody reaction between the surface differentiation antigen of lymphocyte membrane and the fluorescently labeled antibody in human peripheral blood, and the unlabeled cells were dissolved.
- measure
- The percentage of cell groups expressing different markers were counted by the fluorescence detection system on flow cytometry.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * aged 18-45 years * Diagnosis of PCOS with the Rotterdam diagnosis criteria (2003) Exclusion Criteria: * Pregnant women; * Hyperthyroidism or hypothyroidism * Severe liver and kidney function injury * Cancer patients; * Associated with severe infection, severe anemia, neutropenia and other blood system diseases; * Have type 1 diabetes, single-gene mutated diabetes or other secondary diabetes; * Patients with mental illness or intellectual disability; * Have taken drugs for PCOS treatment in the last three months; * Have a long history of taking hormone therapy; * Currently or recently participating in another clinical trial.
References
Publications (0)
Data not yet available